Early phases studies overview
Since 2017 ACCELLENA has been organizing and conducting human pharmacology studies, including first phase studies (including first-in-human studies) and bioequivalence studies.
The company has the capacity and expertise to conduct early research into small molecules and biological products through its own Human Pharmacology Research Center (Phase I Unit).
ACCELLENA is participating in single and multiple dose escalation cohort studies, studies with “3+3” design and others.
The team has considerable experience in conducting pharmacokinetic and pharmacodynamic studies, including bioequivalence studies.
The company has studied the comparative pharmacokinetics of various dosage forms, including sprays, and also has experience in studies with pharmacodynamic end points.
latest update 05/JUL/22